Charles River Laboratories International Inc (CRL) Reports Q3 Earnings
Charles River Laboratories (CRL) exceeds Q3 2025 earnings expectations.
Charles River Laboratories International, Inc. engages in providing products and services to help pharmaceutical and biotechnology companies. The company is headquartered in Wilmington, Massachusetts and currently employs 18,600 full-time employees. The company went IPO on 2000-06-23. The company provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and academic institutions around the globe accelerate their research and drug development efforts. Its Research Models and Services segment includes three businesses that provide foundational tools that enable its clients to discover new molecules: Research Models, Research Model Services, and Cell Solutions. Its Discovery and Safety Assessment segment provides regulated and non-regulated DSA services to support the research, development, and regulatory-required safety testing of potential new drugs, including therapeutic discovery and optimization plus in vitro and in vivo studies, laboratory support services, and strategic non-clinical consulting and program management to support product development. Its Manufacturing Solutions segment includes Microbial Solutions and Biologics Solutions.
Latest news, analyst ratings, earnings reports, dividends, insider trades, and market analysis for Charles River Laboratories International Inc.
Last Updated: Dec 11, 2025, 11:35 PM · Source: Finnhub.io